Back grey_arrow_rt.gif
Myriad Pharmaceuticals Acquires Novel HIV Drug, Bevirimat
  Bevirimat, a First-in-Class Maturation Inhibitor, Represents a New Class of HIV Drugs
January 21, 2009: 06:30 AM ET
Myriad Pharmaceuticals, Inc. today announced that it has acquired all rights to bevirimat from Panacos Pharmaceuticals, Inc. (NASDAQ: PANC) for an upfront payment of $7M.
The upfront payment represents the total payment for bevirimat and will be expensed by Myriad Genetics, Inc. (NASDAQ: MYGN), the parent company of Myriad Pharmaceuticals, during its third fiscal quarter ending March 31, 2009. Myriad Pharmaceuticals has no future milestone or royalty obligations to Panacos. The assets include all patents and patent applications related to the compound, all product inventories, ownership of all clinical data and all rights to regulatory filings. Myriad will assume control of all clinical and commercial development going forward.
"Based on the progress that Panacos has made with bevirimat and the results to date, Myriad Pharmaceuticals believes that bevirimat has great potential for the treatment of patients infected with HIV," said Adrian Hobden Ph.D., President of Myriad Pharmaceuticals, Inc. "We will work diligently to advance this compound through clinical development so that it can become a valuable addition to the drugs currently available to treat this terrible disease."
About Bevirimat
Bevirimat has demonstrated potent activity against a broad range of HIV strains, and laboratory studies have shown bevirimat to be an inhibitor of HIV isolates that are resistant to currently approved HIV drugs. Nearly 650 subjects, including over 100 HIV-infected patients, have been studied in clinical trials. Results from these trials have shown bevirimat to be well tolerated and have demonstrated significant and clinically relevant reductions in viral load in a subset of HIV-infected patients. Epidemiology data show that this subset represents a majority of HIV infected patients. Bevirimat is currently in Phase 2b clinical studies using a new tablet formulation that has an oral bioavailability and pharmacokinetic profile comparable to the previous solution formulation.
Myriad Pharmaceuticals, Inc.
Myriad Pharmaceuticals, Inc. is currently a wholly owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN). Myriad Pharmaceuticals anticipates becoming an independent, publically-traded company by the end of the second calendar quarter of 2009.
Patrick M. Burke
V.P. Corporate and Business Development
e-mail: Email Contact
  icon paper stack View Older Articles   Back to Top